AllergyTalk

Dr. Timothy Chow, Assistant Professor at UT Southwestern and an Assistant Editor of AllergyWatch® and hosts Dr. Gerald Lee, MD, FACAAI and Dr. Stanley Fineman, MD, MBA reviewed the July/August 2025 issue of AllergyWatch®.
Articles Reviewed:
Integrated phase 1 pharmacokinetics and pharmacodynamics of epinephrine administered through sublingual film, autoinjector, or manual injection
Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies
Peanut oral immunotherapy in children with high-threshold peanut allergy
Read archived issues of AllergyWatch®.
Earn CME credit for listening to this episode! Free for College members!
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org!
The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Dr. Shyam Joshi, MD, Associate Professor and Section Chief at Oregon Health & Science University and Associate Editor of AllergyWatch® and hosts Dr. Gerald Lee, MD, FACAAI and Dr. Stanley Fineman, MD, MBA reviewed the May/June 2025 issue of AllergyWatch®.
Articles Reviewed:
Outcomes of intravenous immunoglobulin treatment of immunocompromised patients with viral respiratory infections
A 1-Year Weight Management Program for Difficult-to-Treat Asthma With Obesity: A Randomized Controlled Study
Clustering of clinical symptoms using large language models reveals low diagnostic specificity of proposed alternatives to consensus mast cell activation syndrome criteria
Read archived issues of AllergyWatch®.
Earn CME credit for listening to this episode! Free for College members!
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org!
Speaker Disclosures:
Gerald Lee, MD: No relevant financial relationships with ineligible companies to discloseStanley Fineman, MD: No relevant financial relationships with ineligible companies to discloseShyam Joshi, MD: Advisor: Novartis; Speaker: Novartis; Consultant: Merida Bioscience
The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Dr. Shyam Joshi, MD, Associate Professor and Section Chief at Oregon Health & Science University and Associate Editor of AllergyWatch® and hosts Dr. Gerald Lee, MD, FACAAI and and Dr. Stanley Fineman, MD, MBA reviewed the May/June 2025 issue of AllergyWatch®.
Articles Reviewed:
Association of Allergy Specialty Care and Asthma Outcomes for Medicaid-Enrolled Children
Race-Specific and Race-Neutral Equations for Lung Function and Asthma Diagnosis in Black Children
Anaphylactic degranulation by mast cells requires the mobilization of inflammasome components
Read archived issues of AllergyWatch®.
Earn CME credit for listening to this episode! Free for College members!
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org!
Speaker Disclosures: Gerald Lee, MD: No relevant financial relationships with ineligible companies to discloseStanley Fineman, MD: No relevant financial relationships with ineligible companies to discloseShyam Joshi, MD: Advisor: Novartis; Speaker: Novartis; Consultant: Merida Bioscience
The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Dr. Sarah Spriet, DO, Staff Allergist and Clinical Immunologist at Alexander T. Augusta Military Medical Center in Northern Virginia. She is also a Core Faculty member for the National Capital Consortium Allergy-Immunology fellowship training program and an assistant editor of AllergyWatch® and hosts Dr. Gerald Lee, MD, FACAAI and Dr. Stanley Fineman, MD, MBA reviewed the January/February 2025 issue of AllergyWatch®.
Articles Reviewed:
Persistent cat ownership and asthma in a longitudinal study of Puerto Rican youth
The SQ tree sublingual immunotherapy tablet is effective and well tolerated in children – A pivotal phase III trial
Awareness and application of United States food allergy prevention guidelines among pediatricians and other clinicians
Read archived issues of AllergyWatch®.
Earn CME credit for listening to this episode! Free for College members!
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org!
Speaker Disclosures:Gerald Lee, MD: No relevant financial relationships with ineligible companies to discloseStanley Fineman, MD: No relevant financial relationships with ineligible companies to discloseSarah Spriet, DO: No relevant financial relationships with ineligible companies to disclose
The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Special Episode
ACAAI's Fellows-in-Training Committee leaders Dr. Kylie Jungles, MD and Dr. Amber Hardeman, MD, MPH, MBA sat down with ACAAI's Practice Management Committee chair Dr. Melinda Rathkopf, MD, MBA to discuss advice on landing your first position. Continuing the conversation from Part 1, in this episode, our experts cover how to narrow down your choices, make sense of contracts and negotiations, decide whether to involve a contract lawyer, and plan a smooth transition into your next chapter.
Earn CME credit for listening to this episode! Free for College members!
To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org!
Speaker Disclosures:Amber Hardeman, MD, MPH, MBA: No relevant financial relationships with ineligible companies to discloseKylie Jungles, MD: No relevant financial relationships with ineligible companies to discloseMelinda Rathkopf, MD, MBA, FACAAI: No relevant financial relationships with ineligible companies to disclose
The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Special Episode
ACAAI's Fellows-in-Training Committee leaders Dr. Kylie Jungles, MD and Dr. Amber Hardeman, MD, MPH, MBA sat down with ACAAI's Practice Management Committee chair Dr. Melinda Rathkopf, MD, MBA to share essential tips for fellows-in-training starting their job search. Learn how to choose the right practice setting, create a strategic job search plan, and interview with confidence.
Earn CME credit for listening to this episode! Free for College members!
To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org!
Speaker Disclosures:Amber Hardeman, MD, MPH, MBA: No relevant financial relationships with ineligible companies to discloseKylie Jungles, MD: No relevant financial relationships with ineligible companies to discloseMelinda Rathkopf, MD, MBA, FACAAI: No relevant financial relationships with ineligible companies to disclose
The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Special Episode
On May 16, 2025, the FDA issued an alert regarding a rare but serious side effect of severe pruritus after discontinuing long-term use of cetirizine and levocetirizine. In this episode, we’ll discuss the background of this important announcement and what it means for our patients!
Michael S. Blaiss, MD, Clinical Professor of Pediatrics at the Medical College of Georgia and past-president and former Executive Medical Director of the American College of Allergy, Asthma, and Immunology. He has been a consultant for multiple companies manufacturing second generation antihistamines. Dr. Blaiss was joined by host Dr. Gerald Lee, MD, FACAAI.
Resources:
FDA Drug Safety Communication on Cetirizine and Levocetirizine
ACAAI Advice on Speaking Points Regarding FDA Alert
Previous articles describing this side effect:
Unbearable Pruritus After Withdrawal of (Levo)cetirizine
Pruritus after discontinuation of cetirizine
Make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org!
The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Dr. Sarah Spriet, DO, Staff Allergist and Clinical Immunologist at Alexander T. Augusta Military Medical Center in Northern Virginia. She is also a Core Faculty member for the National Capital Consortium Allergy-Immunology fellowship training program and an assistant editor of AllergyWatch® and hosts Dr. Gerald Lee, MD, FACAAI and Dr. Stanley Fineman, MD, MBA reviewed the January/February 2025 issue of AllergyWatch®.
Articles Reviewed:
A novel syndrome of silent rhinovirus-associated bronchoalveolitis in children with recurrent wheeze
Effects of moderate- versus vigorous-intensity exercise training on asthma outcomes in adults
Human Neutrophils Couple Nitric Oxide Production and Extracellular Trap Formation in Allergic Asthma
Read archived issues of AllergyWatch®.
Earn CME credit for listening to this episode! Free for College members!
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org!
Speaker Disclosures:Gerald Lee, MD: No relevant financial relationships with ineligible companies to discloseStanley Fineman, MD: Researcher: Novartis, Aimmune, DBV; Speaker: GenentechSarah Spriet, DO: No relevant financial relationships with ineligible companies to disclose
The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
 

Dr. Iris Otani, MD, an associate professor of medicine at UCSF and an assistant editor of AllergyWatch® and hosts Dr. Gerald Lee, MD, FACAAI and Dr. Stanley Fineman, MD, MBA reviewed the November/December 2024 issue AllergyWatch®.
Articles Reviewed:
Frequencies and predictors of subcutaneous and intraosseous injection with 4 epinephrine autoinjector devices
Forecasting daily total pollen concentrations on a global scale
Eosinophil Depletion with Benralizumab for Eosinophilic Esophagitis
Read archived issues of AllergyWatch®.
Earn CME credit for listening to this episode! Free for College members!
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org!
Speaker Disclosures:Gerald Lee, MD: No relevant financial relationships with ineligible companies to discloseStanley Fineman, MD: Researcher: Novartis, Aimmune, DBV; Speaker: GenentechIris Otani, MD: Consultant: CSL Behring, Change Healthcare, Adivo Associates
The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Dr. Iris Otani, MD, an associate professor of medicine at UCSF and an assistant editor of AllergyWatch® and hosts Dr. Gerald Lee, MD, FACAAI and Dr. Stanley Fineman, MD, MBA reviewed the November/December 2024 issue AllergyWatch®.
Articles Reviewed:
Effect of Azithromycin on Asthma Remission in Adults With Persistent Uncontrolled Asthma: A Secondary Analysis of a Randomized, Double-Anonymized, Placebo-Controlled Trial
Polyethylene glycol hypersensitivity, patient outcomes in a 7-year retrospective study
Patients taking benralizumab, dupilumab, or mepolizumab have lower postvaccination SARS-CoV-2 immunity
Read archived issues of AllergyWatch®.
Earn CME credit for listening to this episode! Free for College members!
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org!
Speaker Disclosures: Gerald Lee, MD: No relevant financial relationships with ineligible companies to discloseStanley Fineman, MD: Researcher: Novartis, Aimmune, DBV; Speaker: GenentechIris Otani, MD: Consultant: CSL Behring, Change Healthcare, Adivo Associates
The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.